Differences on the Mechanism of Action between the Radiolabeled Somatostatin Receptor Antagonist 177Lu-OPS201 and the Agonist 177Lu-DOTA-TATE: an in vitro Investigation

被引：0
|
作者：
Mansi, R. [1 ]
Santoianni-Klauer, D. [1 ]
Del Pozzo, L. [1 ]
Plas, P. [2 ]
Fani, M. [1 ]
机构：
[1] Univ Basel, Univ Hosp Basel, Basel, Switzerland
[2] Inst Henri Beaufour, Ipsen, Les Ulis, France
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-024
引用
收藏
页码：S14 / S15
页数：2
相关论文
共 50 条
  • [1] The theranostic somatostatin receptor antagonist pair 68Ga-OPS202/177Lu-OPS201 is superior to the agonist pair 68Ga-DOTA-TATE/177Lu-DOTA-TATE: a preclinical and clinical phase I/II study.
    Nicolas, G. P.
    Mansi, R.
    Kaufmann, J.
    Bouterfa, H.
    Maecke, H. R.
    Wild, D.
    Fani, M.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) : 14 - 14
  • [2] Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [177Lu]Lu-OPS201 Compared to the Agonist [177Lu]Lu-DOTA-TATE
    Mansi, Rosalba
    Plas, Pascale
    Vauquelin, Georges
    Fani, Melpomeni
    PHARMACEUTICALS, 2021, 14 (12)
  • [3] 177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
    Beykan, Seval
    Dam, Jan S.
    Eberlein, Uta
    Kaufmann, Jens
    Kjrgaard, Benedict
    Jodal, Lars
    Bouterfa, Hakim
    Bejot, Romain
    Lassmann, Michael
    Jensen, Svend Borup
    EJNMMI RESEARCH, 2016, 6
  • [4] 177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
    Seval Beykan
    Jan S. Dam
    Uta Eberlein
    Jens Kaufmann
    Benedict Kjærgaard
    Lars Jødal
    Hakim Bouterfa
    Romain Bejot
    Michael Lassmann
    Svend Borup Jensen
    EJNMMI Research, 6
  • [5] 177Lu-DOTA-TATE in Peptide Receptor Radionuclide Therapy: first year experience in Turkey
    Kabasakal, L.
    Demirci, E.
    Ocak, M.
    Decristoforo, C.
    Papilla, C.
    Araman, A.
    Uslu, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S428 - S428
  • [6] Design and development of the theranostic pair 177Lu-OPS201/68Ga-OPS202 for targeting somatostatin receptor expressing tumors
    Mansi, Rosalba
    Fani, Melpomeni
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 (10): : 635 - 645
  • [7] Somatostatin antagonist theranostic pair 68Ga-OPS202 and 177Lu-OPS201 for well-differentiated neuroendocrine tumors (NETs)
    Reidy, D.
    Pandit-Taskar, N.
    Krebs, S.
    O'Donoghue, J.
    Raj, N.
    Cruz, E.
    Pham, H.
    Lashley, A.
    Bodei, L.
    Weber, W. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S313 - S313
  • [8] In vitro dose-response comparison of [177Lu]Lu-labelled somatostatin receptor agonist and antagonist
    Tamborino, G.
    De Saint-Hubert, M.
    Struelens, L.
    Dalm, S.
    Ruigrok, E.
    De Jong, M.
    Nonnekens, J.
    Konijnenberg, M. W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S83 - S84
  • [9] Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
    Nicolas, Guillaume P.
    Mansi, Rosalba
    McDougall, Lisa
    Kaufmann, Jens
    Bouterfa, Hakim
    Wild, Damian
    Fani, Melpomeni
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (09) : 1435 - 1441
  • [10] 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
    Thakur, Shilpa
    Daley, Brianna
    Millo, Corina
    Cochran, Craig
    Jacobson, Orit
    Lu, Huiyan
    Wang, Zhantong
    Kiesewetter, Dale
    Chen, Xiaoyuan
    Vasko, Vasyl
    Klubo-Gwiezdzinska, Joanna
    CLINICAL CANCER RESEARCH, 2021, 27 (05) : 1399 - 1409
12345